Compare Equinor ASA (EQNR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Moderna, Inc. — how do they compare? Equinor ASA trades at $43.01 (market cap $101.62B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Equinor ASA is the larger of the two by market cap, and Equinor ASA pays a 3.63% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Moderna, Inc. for 59 Days on average.
| EQNR | MRNA | |
|---|---|---|
Market Cap | $101.62B | $78.65B |
Volume | 4,991,782 | 37,373,437 |
Sector | Energy | Health |
52-Week High | $45.75 | $225.00 |
52-Week Low | $22.41 | $22.36 |
Typical Hold Time | 59 Days | 59 Days |
Enterprise Value | $110.31B | $74.80B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $42.93, up 3.17% today, with a bullish technical outlook supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 2.39, while maintaining strong profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues expanding its LNG portfolio with new Asian supply agreements.
EQNR presents compelling value with significant upside to the $87.50 consensus price target. However, declining revenue and net income margins since 2022, coupled with negative net cash flow trends, warrant caution. The stock's performance remains sensitive to energy market volatility and execution of LNG expansion plans through the early 2030s.
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
